New research published today on bmj.com suggests there is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products. The newly introduced Varenicline is a smoking cessation product of proven effectiveness. However, there have been concerns that it may increase the risk of suicidal behavior and suicide.
Popularity: 1% [?]
Related posts:
- Smoking Cessation Drug Not Linked To An Increased Risk Of Self Harm Or Depression
- Europe Wants Warnings On Champix Smoking Cessation Drug
- Europe Wants Warnings On Champix Smoking Cessation Drug
- Suicide Behavior FDA Public Health Advisory For Chantix – Smoking Cessation Drug
- FDA Adds Strong Warnings To Anti-Smoking Drug Labels
Comments
No Responses to “No Link Between Smoking Cessation Drug And Increased Risk Of Self Harm Or Depression”